Bispecific T cell engagers (TCE) derive from monoclonal antibodies and concomitantly engage a target on the surface of cancer cell and CD3 on the surface of T-cells. TCEs promote T cell activation and lysis of tumor cells. Most TCEs in development for multiple myeloma (MM) target the B ...
Bispecific T cell engagers (BiTEs) kill B cells by engaging T cells. BiTEs are highly effective in acute lymphoblastic leukemia. Here we treated six patients with multidrug-resistant rheumatoid arthritis (RA) with the CD19xCD3 BiTE blinatumomab under compassionate use. Low doses of blinatum...
Immatics’ TCR Bispecifics, called TCER® (T Cell Engaging Receptors), are designed to leverage the therapeutic potential of bispecific T cell engagers exhibiting a well validated mode of action and off-the-shelf usage of bispecific antibodies as well as the expanded target space available to ...
AM Huehls,TA Coupet,CL Sentman 摘要: Bispecific T-cell engagers (BiTEs) are a new class of immunotherapeutic molecules intended for the treatment of cancer. These molecules enhance the patient's immune response to tumors by retargeting T cells to tumor cells. BiTEs are constructed of two ...
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies. The emerging bispecific antibodies (BsAbs), which recruit T cells to tumor cells, exemplified by bispecific T cell engagers (...
Introduction Blinatumomab, first in a class of bispecific T-cell engagers, revolutionized treatment paradigm of B-cell precursor relapsed/refractory or minimal residual disease positive acute lymphoblastic leukemia (ALL) in adults and children, inducing deep remissions in a proportion of patients. However...
Bispecific T cell Engagers 专利名称：Bispecific T cell Engagers 发明人：Margaret Karow,Richard Yau,Jackie Sheng 申请号：US17164699 申请日：20210201 公开号：US20210246222A1 公开日：20210812 专利内容由知识产权出版社提供 专利附图：摘要：Provided are bispecific T Cell Engagers. More specifically, the ...
with BiTE antibodies and other therapeutic approaches. In addition to T cells, innate cell or innate-like cell engagers focusing on innate immunity are gaining increasing attention and have shown potent anti-tumor activity in various cancers, which reflects an orientation toward the future....
bispecific T cell engagers (BiTEs) angiogenesis inhibitors delivery system drug resistance摘要 With the development of molecular cloning technology and the deep understanding of antibody engineering, there are diverse bispecific antibody formats from which to choose to pursue the optimal biological activity ...
With years of experience in the design of T-cell engagers for tumors, scientists at Creative Biolabs have gained a comprehensive perspective on the variables that can impact T-cell engagement. They include the antibody format, membrane proximity of the epitope bound on the tumor antigen, epitopes...